sigvotatug vedotin

News

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.